MAPR

TgMAPR is a mitochondrion-localized cytochrome b5-type heme-binding protein that supports steroidogenesis in Toxoplasma gondii (PMID:37651449). Through its conserved heme-binding cytochrome b5 domain it functions as a hemoprotein (PMID:37651449) and physically associates with the mitochondrial type I CYP450 enzyme TgCYP450mt, forming a redox partnership analogous to mammalian MAPR-CYP450 steroidogenic interactions (PMID:37651449). This partnership sustains a mitochondrial steroidogenic pathway generating hydroxypregnenolone species, deoxycorticosterone, and dehydroepiandrosterone (PMID:37651449). Genetic ablation of TgMAPR reduces parasite steroid levels and produces pleiotropic defects—loss of plasma membrane integrity, aberrant mitochondrial cristae, an abnormally prolonged S-phase, poor fitness, and loss of virulence in mice—establishing the protein as required for parasite steroidogenesis and viability (PMID:37651449). All available evidence derives from a single study; no additional mechanistic detail has been characterized in the available corpus.

1. 2023 Medium

   Establishing the biochemical identity of TgMAPR was needed to place it in a functional class; it was shown to be a cytochrome b5-type hemoprotein.

   Evidence Sequence/domain analysis with experimental validation of hemoprotein identity in Toxoplasma gondii

   PMID:37651449

   Open questions at the time

   • Heme redox properties and electron-transfer chemistry not characterized
   • Domain-level validation only; no structural model
2. 2023 Medium

   Whether TgMAPR acts at a defined organelle was unknown; direct localization placed it at the mitochondrion, implicating it in mitochondrial biology.

   Evidence Subcellular localization by imaging/fractionation in Toxoplasma gondii

   PMID:37651449

   Open questions at the time

   • Submitochondrial topology not resolved
   • Single-lab localization
3. 2023 Medium

   The molecular partner mediating TgMAPR's function was unknown; a physical interaction with the mitochondrial type I CYP450 enzyme TgCYP450mt identified its steroidogenic binding partner.

   Evidence In situ proximity ligation assay in Toxoplasma gondii

   PMID:37651449

   Open questions at the time

   • Proximity assay without reciprocal biochemical validation
   • Direct electron/heme transfer to TgCYP450mt not demonstrated
4. 2023 High

   The physiological requirement for TgMAPR was undefined; knockout linked its loss to a mitochondrial steroidogenic pathway and to pleiotropic fitness and virulence defects.

   Evidence Genetic knockout (ΔTgMAPR) with growth, cell-cycle, metabolomic steroid quantification, and mouse virulence assays in Toxoplasma gondii

   PMID:37651449

   Open questions at the time

   • Causal chain from reduced steroids to membrane/mitochondrial/cell-cycle defects not dissected
   • Whether phenotypes are direct or downstream of steroid loss unresolved
5. 2023 High

   The specific metabolic output supported by TgMAPR was unknown; metabolomics placed it in production of hydroxypregnenolone species, deoxycorticosterone, and dehydroepiandrosterone.

   Evidence LC-MS targeted metabolomics comparing ΔTgMAPR to wild-type parasites

   PMID:37651449

   Open questions at the time

   • Enzymatic step catalyzed within the pathway not defined
   • Functional role of these steroids in the parasite unknown

• How TgMAPR's heme chemistry mechanistically drives TgCYP450mt-dependent steroidogenesis, and how steroid loss produces the membrane, mitochondrial, and cell-cycle phenotypes, remain unresolved.
• No reconstitution of the TgMAPR-TgCYP450mt catalytic cycle
• Mechanistic link between steroids and downstream phenotypes untested
• All findings from a single study